CRP and major depressive disorder: Tumour necrosis factor alpha (TNFα) blockade, for example, improved depressive symptoms in patients with treatment-resistant depression, but only in patients with high baseline CRP levels [3], suggesting that the anti-inflammatory therapy targets processes independent of the etiological mechanisms underlying major depressive disorder (MDD).